Dr Reddy's Laboratories has received approval from Health Canada to sell a generic version of the diabetes drug semaglutide, making it the first company to get market authorisation for a generic semaglutide injection in Canada and the first in a G7 country.
At the heart of this debate is Section 3(d) of the Patents Act, a safeguard designed to prevent drugmakers from extending monopoly protection through trivial modifications to existing medicines.
Made in Korea had the potential to be a culturally rich coming-of-age story but settles for a generic template with an underdeveloped location setting, notes Sreeju Sudhakaran.
Biocon is actively seeking in-licensing opportunities to expand its biosimilars portfolio, focusing on products that complement existing therapy areas, as the company shifts to a 'consolidate' phase with a strong emphasis on improving capacity utilisation, expanding margins, and driving return on capital employed.
Dhruv Sarja's KD: The Devil attempts to deliver a grounded action experience but ultimately succumbs to a loud, generic gangster narrative, muddled storytelling, and excessive theatrics, sighs Arjun Menon.
The fast-growing GLP-1 market, propelled by lower-cost generics following patent expiry, is widening availability beyond patients with obesity and diabetes -- but also driving unsupervised, appearance-led demand, according to doctors.
Kiran Mazumdar-Shaw names niece Claire Mazumdar as successor at Biocon. Explore the leadership transition, strategy, and future plans.
Piramal Pharma anticipates a significant turnaround in financial year 2026-27 (FY27), projecting early-to-mid teens revenue expansion and a sharp improvement in profitability, driven by improved business momentum, new product acquisitions, and structural tailwinds.
Sun Pharmaceutical Industries Ltd has announced its acquisition of US-based Organon & Co in an all-cash deal valued at an enterprise valuation of USD 11.75 billion, aiming to become a top 25 global pharmaceutical company.
Sun Pharmaceutical Industries' acquisition of US-based Organon & Co. for $11.75 billion, the largest overseas acquisition by an Indian pharma company, has been met with mixed reactions from brokerages, who see strategic entry into women's health and biosimilars but also flag potential integration challenges and debt concerns.
The strength of the human spirit in the face of oppression and collective action is a theme well suited to these divided times, but Pallichattambi needed to be more precise and focused in its imagination to the make the noble intentions stick, notes Arjun Menon.
Indian youth creates fictional AI influencer, Emily Hart, who amasses millions of followers and earns him substantial income, exposing the deceptive potential of AI in the digital age.
While the introduction of branded generics is likely to accelerate volumes for GLP-1 agonists, value growth may moderate because of price erosion.
Inspections conducted across 49 entities including pharmacies, wholesalers, and clinics to detect violations and misleading marketing practices.
'Infertility and reproductive health challenges, much like other chronic conditions, are rising globally.'
For decades, multinational pharmaceutical companies and Indian drugmakers worked in ways that supported each other: MNCs brought innovation and brands, while Indian companies built scale through generics and cost efficiency. There was an important overlap - generic drugs - but this is shrinking fast. And the consequences are reshaping India's gigantic pharmaceutical market.
This Mummy is all sound and fury, signifying nothing, discovers Mayur Sanap.
'The unregulated marketing has to stop. People are getting recommendations for this from gym trainers, from marriage counsellors -- that is simply unacceptable.' ''There are many ways to lose weight -- eat less, fast, exercise, eat healthy. That is how you lose weight.'
Biocon aims to become the world's leading insulin company, capitalising on larger pharmaceutical rivals' strategic shift towards newer, high-margin GLP-1 diabetes therapies. The company plans to expand its insulin presence across 80 markets, focusing on value maximisation and addressing the indispensable need for insulin, particularly for Type-1 and late-stage Type-2 diabetics.
Ramayana, which is being mounted as a two-part cinematic event, will soar. The music, visuals, technical finesse and the promise of strong performances not just tease a film, it teases a grand experience, notes Mayur Sanap.
Abbott will exclusively distribute and market Extensior in the country, becoming the second company to secure sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma.
10 stocks from the Nifty 200 index that offer good growth potential and scope to deliver decent returns from current levels, based on brokerage estimates.
Artificial intelligence (AI) is no longer a side conversation for Indian pharma. It is fast becoming central to how drugs will be discovered, made, and supplied. Along with that shift comes a sharper focus on innovation, on the one hand, and quality and trust, on the other.
Cognizant's research reveals that companies seeking AI adoption favour IT services firms offering custom, full-stack AI solutions, prioritising flexibility and expertise over cost and speed.
There are hopes of a turnaround in overall corporate earnings after six quarters of single digit growth.
'Any promotional activity carried out under the pretext of disease awareness, influencer engagement, corporate campaigns, or similar activities that create brand recall/product visibility of the prescription shall also be treated as violations.'
Delhi High Court has cleared the way for Zydus Lifesciences to proceed with the sale of its version of the cancer drug nivolumab in India. nivolumab is used to treat several types of cancer by activating the body's immune system to target carcinogenic cells.
A strong third-quarter (October-December/Q3) performance for 2025-26 (FY26) has helped the stock of India's largest listed pharmaceutical (pharma) company, Sun Pharmaceutical Industries, gain about 7 per cent since the start of February.
Buoyant domestic sales are expected to lift revenues for pharma companies by 8-11 per cent in Q3FY26, even as declining generic Revlimid (cancer drug) sales in the US remain a key drag. Most brokerages forecast a modest 2-4 per cent growth in profit after tax (PAT) for the quarter. Hospitals and diagnostics companies, meanwhile, are likely to post much stronger numbers, with revenues seen growing 20-22 per cent year-on-year (Y-o-Y).
From 20 hours of non-stop celebrations to a 12-day wedding event in Ahmedabad featuring over 300 artistes, Devanshi Patel of Shreem Events tells us how she has handled challenging wedding demands.
'Nitish Kumar may be marginalised as an office-holder, but that is not the same thing as the disappearance of Nitish Kumar's politics.'
Ustaad Bhagat Singh is less a film and more, a lazily constructed vehicle for star worship and political signalling, one that quickly wears out its welcome for anyone outside Pawan Kalyan's core fanbase, observes Sreeju Sudhakaran.
Both countries commit to provide each other preferential market access in sectors of respective interest on a sustained basis
The Central Information Commission (CIC) has directed the Income Tax Department to disclose 'generic details of the net taxable income/gross income' of an estranged husband to his wife for pursuing maintenance proceedings. The commission stated that such information cannot be denied on privacy grounds in matrimonial disputes.
An Indian AI Research Organisation official says India has adopted a balanced and pragmatic approach to AI regulation, avoiding the extremes of the US and EU models.
The European Union's (EU's) offer to slash tariffs on 97.5 per cent of Indian chemical exports to zero is set to give India's pharmaceutical and medical device firms preferential access to the European markets.
US and India will promptly implement this framework and work towards finalising the interim agreement with a view to concluding a mutually beneficial bilateral trade agreement.
The Centre has allowed companies to begin lab testing immediately after filing applications instead of waiting for detailed scrutiny, in a move to expedite approvals for manufacture, or import of new drugs.
'Filmmaking is such a weird line of work, artistic expression and collaboration.' 'It is letting go, then holding on to something, being democratic and then being tyrannical.'
Alliances fight wars effectively only when they share an endgame. If Israel acted without US knowledge, then the military alliance is operating without real coordination at the level of strategic targeting. Neither picture is reassuring in a war that is no longer regional in its consequences. Prem Panicker continues his must read daily blog on the Gulf War.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances